Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aromatase inhibitor effects on blood lipids and statin prognosis in postmenopausal hormone receptor-positive breast cancer
ChiCTR1900024790Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of exemestane, letrozole and anastrozole in breast cancer and dyslipidemia (2 arms), sponsored by First Hospital of China Medical University. Primary endpoints: Percentage of patients with dyslipidemia and 5-year disease-free survival. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
exemestaneletrozoleanastrozole
03
Conditions
breast cancerdyslipidemia
Beyond the preview
Go deeper on ChiCTR1900024790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024790.